Global Blood Transfusion Diagnostics Market Size, Share, Opportunities, And Trends By Type (Instruments, Kits & Reagents), By Technology (ELISA, Western Blotting, Nucleic Acid Amplification, Others), By End-User (Hospitals And Clinics, Diagnostic Labs, Blood Banks), And By Geography - Forecasts From 2024 To 2029

The global blood transfusion diagnostics market was valued at US$4.230 billion in 2022 and is expected to grow at a CAGR of 6.07% over the forecast period to reach a total market size of US$6.389 billion by 2029.

Blood transfusion diagnostics refers to testing conducted on blood and blood components before transfusion to patients. To avoid adverse reactions or infection transmission, each blood unit must be checked for blood group type and disease screening. It is an essential component of transfusion treatment since it offers vital information to healthcare practitioners and validates the compatibility of donor and recipient blood samples. Red blood cells are the most frequently transfused blood products. Molecular blood group diagnosis is one of the transfusion diagnostics. For patients with antibodies against clinically relevant, uncommon, or weak antigens, molecular blood group diagnosis allows for safer blood storage and on-demand supplies.

Developing and underdeveloped countries lack proper blood banks, medical equipment required for blood transfusion, adequate conditions for blood storage, and a limited supply of blood in response to high demand. Hospitals lack the necessary amenities to deliver hygienic and safe transfusions. Thus, the escalating burden of chronic disorders and the rising need for donor screening are boosting the market’s growth. Furthermore, the rising need for transfusions because of trauma, car accidents, and surgical procedures is favorably influencing the market.

The emergence of advanced molecular platforms by market leaders accelerates the transition from manual testing and equipment to semi-automated and fully automated devices. These automated systems have been critical in detecting transfusion transmissible infections (TTIs) in blood samples and can accurately remove human error throughout the transfusion procedure.

During the forecast period, North America is expected to be the largest regional market for the global blood transfusion diagnostics market. This dominance can be attributed to increased acceptance of the blood transfusion procedure, increased public awareness regarding blood donations, and developed healthcare infrastructure. According to data released by the National Center for Biotechnology Information, over 15 million blood units are transfused in the United States each year, with an estimated 85 million units transfused globally.

MARKET DRIVER:

• Blood and blood components are in high demand is anticipate in the market growth

The rising prevalence of blood-related conditions such as hemophilia, cancer, thrombocytopenia, and others, as well as chronic kidney disease (CKD), has increased the demand for blood transfusions. According to World Kidney Day estimates, about 850 million individuals worldwide will be suffering from kidney diseases in 2020. In addition, one out of every ten individuals has chronic kidney disease (CKD), which is predicted to become the sixth leading cause of death by the end of 2040. Furthermore, the growing number of patients suffering from anemia necessitates red blood cell transfusion for treatment, which is further driving up the demand for blood transfusion diagnostics. The World Health Organization (WHO) estimates that anaemia affects around 1.62 billion people worldwide. This, together with increased awareness regarding blood safety from infectious diseases through various initiatives in developed and developing nations, is driving up demand for blood screening tests and other diagnostic instruments.

MARKET RESTRAINTS:

• The high cost of instruments and a lack of infrastructure

Despite the rising prevalence of chronic blood disorders and increased demand for blood transfusions, several issues are impeding the market’s growth. One of the causes is a lack of investment in healthcare infrastructure and strict government policies, particularly in developing nations when compared to developed countries. Furthermore, the high cost of tests, instruments, and reagents, along with a shortage of qualified professionals to handle automated diagnostic solutions, is one of the factors restraining the growth of the blood transfusion diagnostics market during the forecast period.

Competitive insight:

Officials from the State Blood Transfusion Council (SBTC) reported in September 2021 that supplies in Maharashtra blood banks would barely last a week. This drop was attributed to a decrease in blood donation camps, reduced donor footfall owing to the pandemic, and the closure of offices and institutions in the state.

The American Red Cross started a new nationwide initiative in September 2021 to reach out to more black blood donors to aid patients with sickle cell disease and improve health outcomes. Blood donations from individuals of the same race or ethnicity as well as blood type are the most reliable option to treat sickle cell patients.

Key Developments:

• March 2023- MedGenome Labs has introduced the FSHD1 genetic screening test, the Optical Genome Mapping Test (OGM), to assess early-stage genetic changes in patients with Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1). This advanced diagnostic tool uses advanced technology to provide a comprehensive and accurate assessment of genetic changes, detecting both large-scale insertions and duplications, as well as subtle DNA changes.
• May 2021- F. Hoffmann-La Roche Ltd and Bio-Rad Laboratories, Inc. have partnered to offer customers access to Bio-Rad's InteliQ products and Unity QC data management solutions. The partnership aims to enhance workflow efficiency and improve analytical performance in laboratories. Bio-Rad's InteliQ products, including barcoded quality control tubes, are part of the alliance.

Global Blood Transfusion Diagnostics Market Scope:

 

Report Metric	Details
Market Size Value in 2022	US$4.230 billion
Market Size Value in 2029	US$6.389 billion
Growth Rate	CAGR of 6.07% from 2022 to 2029
Base Year	2022
Forecast Period	2024 – 2029
Forecast Unit (Value)	USD Billion
Segments Covered	Type Technology End-User Geography
Companies Covered	Quotient Ltd. BAG Healthcare Abbott Immucor Diasorin SPA And more
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Type
  • Instruments
  • Kits & Reagents
• By Technology
  • ELISA
  • Western Blotting
  • Nucleic Acid Amplification
  • Others
• By End-User
  • Hospitals & Clinics
  • Diagnostic Labs
  • Blood Banks
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • Taiwan
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY TYPE

5.1. Introduction

5.2. Instruments

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Kits & Reagents

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1. Introduction

6.2. ELISA

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Western Blotting

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Nucleic Acid Amplification

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

6.5. Others

6.5.1. Market Opportunities and Trends

6.5.2. Growth Prospects

6.5.3. Geographic Lucrativeness

7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER

7.1. Introduction

7.2. Hospitals & Clinics

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Diagnostic Labs

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

7.4. Blood Banks

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

7.4.3. Geographic Lucrativeness

8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Type

8.2.2. By Technology

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Opportunities and Trends

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Opportunities and Trends

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Opportunities and Trends

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Type

8.3.2. By Technology

8.3.3. By End-User

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Opportunities and Trends

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Opportunities and Trends

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Opportunities and Trends

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Type

8.4.2. By Technology

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.1.1. Market Opportunities and Trends

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Opportunities and Trends

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Opportunities and Trends

8.4.4.3.2. Growth Prospects

8.4.4.4. Italy

8.4.4.4.1. Market Opportunities and Trends

8.4.4.4.2. Growth Prospects

8.4.4.5. Spain

8.4.4.5.1. Market Opportunities and Trends

8.4.4.5.2. Growth Prospects

8.4.4.6. Others

8.4.4.6.1. Market Opportunities and Trends

8.4.4.6.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Type

8.5.2. By Technology

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Opportunities and Trends

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Opportunities and Trends

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Opportunities and Trends

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Type

8.6.2. By Technology

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Opportunities and Trends

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Opportunities and Trends

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Opportunities and Trends

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Opportunities and Trends

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Opportunities and Trends

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Opportunities and Trends

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Opportunities and Trends

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Opportunities and Trends

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Quotient Ltd.

10.2. BAG Healthcare

10.3. Abbott

10.4. Immucor

10.5. Diasorin SPA

10.6. Bio-Rad Laboratories Inc.

10.7. Grifols S.A.

10.8. F. Hoffmann La Roche Ltd.

10.9. Beckman Coulter Inc.

10.10. DIAGAST

Quotient Ltd.

BAG Healthcare

Abbott

Immucor

Diasorin SPA

Bio-Rad Laboratories Inc.

Grifols S.A.

F. Hoffmann La Roche Ltd.

Beckman Coulter Inc.

DIAGAST